Celgene just hit a major setback with its next blockbuster drug (CELG)
AP/Mike Derer
- Celgene said Tuesday that the FDA refused to review its multiple sclerosis drug Ozanimod for approval.
- "Upon its preliminary review, the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review," Celgene said in a news release. NDA is short for new drug application.
- Ozanimod, if approved, is expected to make as much as $2 billion in peak sales.
- Celgene has had a difficult couple of months. Читать дальше...